Related content

Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial

By Koukourakis M.I.   Kourousis C.   Kamilaki M.   Koukouraki S.   Giatromanolaki A.   Kakolyris S.   Kotsakis A.   Androulakis N.   Bahlitzanakis N.   Georgoulias V.  

European Journal of Cancer, Vol. 34, Iss. 6, 1998-05 ,pp. : 838-844

Elsevier

Access to resources Recommend Favorite

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial

By Stathopoulos G. P.   Katis C.   Tsavdaridis D.   Dimitroulis J.   Karaindros D.   Stathopoulos J.   Dimou E.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 555-560

Springer Publishing Company

Access to resources Recommend Favorite

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

By Lalisang R.   Erdkamp F.   Rodenburg C.   Knibbeler-van Rossum C.   Nortier J.   Bochove A.   Slee P.   Voest E.   Wils J.   Wals J.   Loosveld O.   Smals A.   Blijham G.   Tjan-Heijnen V.   Schouten H.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 437-445

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer - a phase II trial

By Laack E.   Mende T.   Benk J.   Chemaissani A.   Scholtze J.   Lorenz C.   Niestroy A.   Dalhoff K.   Muller T.   Walter T.   Durk H.   Edler L.   Hossfeld D.K.  

European Journal of Cancer, Vol. 37, Iss. 5, 2001-03 ,pp. : 583-590

Elsevier

Access to resources Recommend Favorite